---
figid: PMC5541669__nihms879817f3
figlink: /pmc/articles/PMC5541669/figure/F3/
number: F3
caption: Systematic analysis of genes in pathways upstream of the nuclear factor-κB
  (NF-κB) complex revealed a large repertoire of diffuse large B cell lymphoma (DLBCL)-specific
  genetic alterations in B cell receptor (BCR) and myeloid differentiation primary
  response 88 (MYD88) pathways. The presence of these mutations leads to aberrant
  activation of the canonical p50-RELA heterodimer and associated tumour dependency.
  These mutations, which are more frequent in the activated B cell (ABC) subtype of
  DLBCL, have provided the rationale for the clinical development of several BCR pathway
  inhibitors, such as ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor. CARD11,
  caspase recruitment domain family member 11; IFN, interferon; IL, interleukin; IRAK,
  IL-1 receptor-associated kinase; IRF4, interferon regulatory factor 4; ITAM, immune
  receptor tyrosine-based activation motif; JAK1, Janus kinase 1; MALT1, mucosa-associated
  lymphoid tissue lymphoma translocation protein 1; PKC, protein kinase C; STAT, signal
  transducer and activator of transcription; TIR, Toll-interleukin receptor; TRAF6,
  TNF receptor associated factor 6. Adapted with permission from REF. , Nature Publishing
  Group.
pmcid: PMC5541669
papertitle: The recurrent architecture of tumour initiation, progression and drug
  sensitivity.
reftext: Andrea Califano, et al. Nat Rev Cancer. ;17(2):116-130.
pmc_ranked_result_index: '94752'
pathway_score: 0.9648277
filename: nihms879817f3.jpg
figtitle: Recurrent architecture of tumour initiation, progression and drug sensitivity
year: ''
organisms:
- Homo sapiens
ndex: 93b5004b-ded3-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5541669__nihms879817f3.html
  '@type': Dataset
  description: Systematic analysis of genes in pathways upstream of the nuclear factor-κB
    (NF-κB) complex revealed a large repertoire of diffuse large B cell lymphoma (DLBCL)-specific
    genetic alterations in B cell receptor (BCR) and myeloid differentiation primary
    response 88 (MYD88) pathways. The presence of these mutations leads to aberrant
    activation of the canonical p50-RELA heterodimer and associated tumour dependency.
    These mutations, which are more frequent in the activated B cell (ABC) subtype
    of DLBCL, have provided the rationale for the clinical development of several
    BCR pathway inhibitors, such as ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor.
    CARD11, caspase recruitment domain family member 11; IFN, interferon; IL, interleukin;
    IRAK, IL-1 receptor-associated kinase; IRF4, interferon regulatory factor 4; ITAM,
    immune receptor tyrosine-based activation motif; JAK1, Janus kinase 1; MALT1,
    mucosa-associated lymphoid tissue lymphoma translocation protein 1; PKC, protein
    kinase C; STAT, signal transducer and activator of transcription; TIR, Toll-interleukin
    receptor; TRAF6, TNF receptor associated factor 6. Adapted with permission from
    REF. , Nature Publishing Group.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - IFNB1
  - PIK3R6
  - IFNA1
  - CD79B
  - TNFAIP3
  - PIK3R5
  - CARD11
  - CD79A
  - PIK3CG
  - IRAK1
  - IL10
  - IL6
  - STAT3
  - SYK
  - AKT3
  - STAT1
  - TYK2
  - AKT2
  - PIK3R3
  - TRAF6
  - AKT1
  - MYD88
  - NFKB1
  - PRKCB
  - BTK
  - IRAK4
  - IRF4
  - PIK3R4
  - PIK3CA
  - MTOR
  - PIK3CB
  - JAK1
  - MALT1
  - BCL10
  - BCR
  - PIK3CD
  - Temsirolimus
  - Enzastaurin
  - Ruxolitinib
  - Ibrutinib
genes:
- word: IFNB
  symbol: IFNB
  source: bioentities_symbol
  hgnc_symbol: IFNB1
  entrez: '3456'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: IFN
  symbol: IFN
  source: hgnc_alias_symbol
  hgnc_symbol: IFNA1
  entrez: '3439'
- word: CD79B
  symbol: CD79B
  source: hgnc_symbol
  hgnc_symbol: CD79B
  entrez: '974'
- word: A20
  symbol: A20
  source: hgnc_alias_symbol
  hgnc_symbol: TNFAIP3
  entrez: '7128'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: CARD11
  symbol: CARD11
  source: hgnc_symbol
  hgnc_symbol: CARD11
  entrez: '84433'
- word: CD79A
  symbol: CD79A
  source: hgnc_symbol
  hgnc_symbol: CD79A
  entrez: '973'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: IRAK1
  symbol: IRAK1
  source: hgnc_symbol
  hgnc_symbol: IRAK1
  entrez: '3654'
- word: IL-10
  symbol: IL-10
  source: hgnc_alias_symbol
  hgnc_symbol: IL10
  entrez: '3586'
- word: IL-6
  symbol: IL-6
  source: hgnc_alias_symbol
  hgnc_symbol: IL6
  entrez: '3569'
- word: STAT3
  symbol: STAT3
  source: hgnc_symbol
  hgnc_symbol: STAT3
  entrez: '6774'
- word: SYK
  symbol: SYK
  source: hgnc_symbol
  hgnc_symbol: SYK
  entrez: '6850'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: STAT1
  symbol: STAT1
  source: hgnc_symbol
  hgnc_symbol: STAT1
  entrez: '6772'
- word: TYK2
  symbol: TYK2
  source: hgnc_symbol
  hgnc_symbol: TYK2
  entrez: '7297'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: TRAF6
  symbol: TRAF6
  source: hgnc_symbol
  hgnc_symbol: TRAF6
  entrez: '7189'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: MYD88
  symbol: MYD88
  source: hgnc_symbol
  hgnc_symbol: MYD88
  entrez: '4615'
- word: NF-KB
  symbol: NF-kappaB
  source: hgnc_alias_symbol
  hgnc_symbol: NFKB1
  entrez: '4790'
- word: PKCB
  symbol: PKCB
  source: hgnc_prev_symbol
  hgnc_symbol: PRKCB
  entrez: '5579'
- word: BTK
  symbol: BTK
  source: hgnc_symbol
  hgnc_symbol: BTK
  entrez: '695'
- word: IRAK4
  symbol: IRAK4
  source: hgnc_symbol
  hgnc_symbol: IRAK4
  entrez: '51135'
- word: IRF4
  symbol: IRF4
  source: hgnc_symbol
  hgnc_symbol: IRF4
  entrez: '3662'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: JAK1
  symbol: JAK1
  source: hgnc_symbol
  hgnc_symbol: JAK1
  entrez: '3716'
- word: MALT1
  symbol: MALT1
  source: hgnc_symbol
  hgnc_symbol: MALT1
  entrez: '10892'
- word: BCL-10
  symbol: BCL10
  source: hgnc_symbol
  hgnc_symbol: BCL10
  entrez: '8915'
- word: BCR
  symbol: BCR
  source: hgnc_symbol
  hgnc_symbol: BCR
  entrez: '613'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
chemicals:
- word: Temsirolimus
  source: MESH
  identifier: C401859
- word: Enzastaurin
  source: MESH
  identifier: C504878
- word: Ruxolitinib
  source: MESH
  identifier: C540383
- word: Ibrutinib
  source: MESH
  identifier: C551803
diseases: []
figid_alias: PMC5541669__F3
redirect_from: /figures/PMC5541669__F3
figtype: Figure
---
